2 대 3 HPV 용량의 면역 반응 비교(27-45세)
27-45세 여성의 FDA 승인 9가 HPV 백신 2회 투여와 3회 투여 후 면역 반응 비교
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
연구 개요
상태
상세 설명
The investigators are studying an alternate dosing regimen of an approved drug (9vHPV vaccine) in the population for which it is approved. The vaccine is approved for individuals ages 9-45 years old and participants in this study will be 27-45 years of age. The purpose of the study is to examine the immune response of 2 doses of 9vHPV vaccine. The current recommendation is to administer the vaccine in 3 doses (administered at 0, 1-2 months and 6 months) to those 15-45 years of age, but only 2 doses (administered at 0 and 6 months) if the vaccine series is initiated before age 15. The investigators will conduct a randomized study to determine if 2 doses of elicit a similar immune response to that of a standard 3 dose series in individuals 27-45 years of age. Participants in the study group will receive 2 doses of at 0 and 6 months. Participants in the control group will receive 3 doses of 9vHPV vaccine at 0, 2 months, and 6 months. All participants (target accrual n=618) will have 5 mLs of blood drawn at 0, 1, 7, and 12 months. Following the 12-month blood draw, participants randomized to 2-doses will be offered the 3rd dose. Potential participants will be recruited through the University of Texas Medical Branch (UTMB) clinics and surrounding community, and will be screened for inclusion/exclusion criteria. Eligible patients will sign an informed written consent. At their baseline visit, participants will have their blood drawn, be randomized into either the study or control group, and receive their first dose of the HPV vaccine. All participants will receive compensation administered through a ClinCard following each of the 4 blood draws.
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Texas
-
Galveston, Texas, 미국, 77555
- University of Texas Medical Branch
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
- Females 27-45 years old.
- Ability to give informed consent.
- Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.
- Reliable telephone access for the duration of the project.
- Can read and speak in either English or Spanish.
- Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.
- Reports consistent use of reliable birth control and plans to continue its use through study month 13.
Exclusion criteria:
- Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.
- Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
- Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint/soft tissue will be considered eligible for the study.
- History of splenectomy
- Known allergies to any vaccine components, including aluminum, yeast or Benzonase.
- Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.
- History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- History of >10 sexual partners in their lifetime at time of enrollment
- Plans to move out of the Galveston/Houston area in the 13 months following study entry.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Females, 3-dose standard
Three doses of the 9-valent HPV vaccine to be administered to the comparison group (27-45 years of age) at 0, 2, and 6 months. |
This will be the comparison group for the 2-dose group. |
|
실험적: Females, 2-dose alternative
Two doses of the 9-valent HPV vaccine to be administered to the experimental group (27-45 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months. |
Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-6, measured as number of participants. |
Month 1
|
|
Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-6, measured as number of participants. |
Month 7
|
|
Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-6, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-11
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-11, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-11
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-11, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-11
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-11, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-16
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-16, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-16
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-16, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-16
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-16, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-18
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-18, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-18
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-18, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-18
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-18, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-31
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-31, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-31
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-31, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-31
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-31, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-33
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-33, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-33
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-33, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-33
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-33, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-45
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-45, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-45
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-45, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-45
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-45, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-52
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-52, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-52
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-52, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-52
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-52, measured as number of participants. |
Month 12
|
|
Short-term HPV type-specific antibody response for type HPV-58
기간: Month 1
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-58, measured as number of participants. |
Month 1
|
|
Short-term HPV type-specific antibody response for type HPV-58
기간: Month 7
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-58, measured as number of participants. |
Month 7
|
|
Short-term HPV type-specific antibody response for type HPV-58
기간: Month 12
|
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-58, measured as number of participants. |
Month 12
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Abbey B Berenson, MD, PhD, University of Texas
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 22-0243
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .